{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:43:17Z","timestamp":1792176197546,"version":"4.4.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dutch Neuromuscular Foundation","award":["W.OR19-05"],"award-info":[{"award-number":["W.OR19-05"]}]},{"name":"Dutch JDM Charity Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>JDM is a rare chronic inflammatory disorder of childhood. The aim of this prospective study was to describe the characteristics and outcomes of the Dutch JDM population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Demographics, clinical features, diagnostic test results and treatment were prospectively evaluated at diagnosis and during follow-up visits in JDM patients diagnosed between 2007 and 2024 in the study-coordinating centre and between 2015 and 2024 in five other tertiary referral hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 83 patients were included (65% female). Median age at diagnosis was 6.0\u2009years (IQR 4\u20139). Median follow-up was 3.2\u2009years (IQR 1.4\u20135.8). The most common features at diagnosis were proximal muscle weakness (94.9%) and Gottron\u2019s papules\/sign (79.7%). While CK was abnormal in 73.1%, IFN-related biomarkers Galectin-9 and CXCL10 were elevated in 98.3% and 93.3% at diagnosis, respectively. Whole-body MRI showed muscle oedema in 30\/33 (90.9%) patients. Corticosteroids could be tapered to 0.2\u2009mg\/kg at 6\u2009months in 41.5%. Of all patients, 27 (32.5%) experienced one or more flares and 24 (28.9%) had a refractory disease course. Calcinosis occurred in 12 patients (14.5%). At last follow-up, 28.9% of patients had clinically inactive disease without medication. No patient died.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates the superior diagnostic sensitivity of Galectin-9 and CXCL10 over CK, the high sensitivity of MRI and the frequent occurrence of refractory disease and flares despite treatment. Reliable predictors are needed to identify patients who can safely taper immunosuppressants versus those needing continued treatment, and who may benefit from targeted therapies initiated upfront.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf335","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T07:24:10Z","timestamp":1750058650000},"page":"5622-5628","source":"Crossref","is-referenced-by-count":8,"title":["Advances in JDM: biomarker and MRI sensitivity, outcomes and steroid management in a Dutch national prospective cohort"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-353X","authenticated-orcid":false,"given":"Saskia R","family":"Veldkamp","sequence":"first","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"van der Griend","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsbeth","family":"Noppers","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wineke","family":"Armbrust","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology and Immunology, Beatrix Children\u2019s Hospital, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Merlijn","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Department of Paediatric Immunology, Rheumatology and Infectious Diseases, Emma Children\u2019s Hospital, Amsterdam University Medical Centres, Location AMC , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra C E","family":"Hissink Muller","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Willem Alexander Children\u2019s Hospital, Leiden University Medical Centre , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Hoppenreijs","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Amalia Children\u2019s Hospital, Radboud University Medical Centre Nijmegen , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-352X","authenticated-orcid":false,"given":"Sylvia","family":"Kamphuis","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Sophia Children\u2019s Hospital, Erasmus University Medical Centre , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Wienke","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"van Wijk","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet","family":"van Royen-Kerkhof","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H A","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2025110820503336400_keaf335-B1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology"},{"key":"2025110820503336400_keaf335-B2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2025110820503336400_keaf335-B3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2025110820503336400_keaf335-B4","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025110820503336400_keaf335-B5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025110820503336400_keaf335-B6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025110820503336400_keaf335-B7","doi-asserted-by":"crossref","first-page":"101976","DOI":"10.1016\/j.berh.2024.101976","article-title":"Personalised medicine in juvenile dermatomyositis: from novel insights in disease mechanisms to changes in clinical practice","volume":"38","author":"Veldkamp","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025110820503336400_keaf335-B8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.rdc.2021.07.003","article-title":"Updates on juvenile dermatomyositis from the last decade: classification to outcomes","volume":"47","author":"Kim","year":"2021","journal-title":"Rheum Dis Clin N Am"},{"key":"2025110820503336400_keaf335-B9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2025110820503336400_keaf335-B10","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/acr.22041","article-title":"Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis","volume":"65","author":"Qui\u00f1ones","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2025110820503336400_keaf335-B11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.39200","article-title":"Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated","volume":"67","author":"Almeida","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025110820503336400_keaf335-B12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025110820503336400_keaf335-B13","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1093\/rheumatology\/keaa371","article-title":"Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis","volume":"60","author":"Kishi","year":"2021","journal-title":"Rheumatology"},{"key":"2025110820503336400_keaf335-B14","author":"CBS"},{"key":"2025110820503336400_keaf335-B15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1525-1470.2007.00364.x","article-title":"Dermatomyositis with a pityriasis rubra pilaris-like eruption: an uncommon cutaneous manifestation in dermatomyositis","volume":"24","author":"Polat","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"2025110820503336400_keaf335-B16","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.20179","article-title":"Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies","volume":"50","author":"Huber","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2025110820503336400_keaf335-B17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12969-019-0326-5","article-title":"The PRINTO evidence-based proposal for glucocorticoids tapering\/discontinuation in new onset juvenile dermatomyositis patients","volume":"17","author":"Giancane","year":"2019","journal-title":"Pediatr Rheumatol"},{"key":"2025110820503336400_keaf335-B18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/rheumatology\/kel099","article-title":"The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)\u2014clinical characteristics of children recruited within the first 5\u2009yr","volume":"45","author":"McCann","year":"2006","journal-title":"Rheumatology"},{"key":"2025110820503336400_keaf335-B19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1756-185X.12107","article-title":"Clinical features and disease course of patients with juvenile dermatomyositis","volume":"16","author":"Gowdie","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"2025110820503336400_keaf335-B20","doi-asserted-by":"crossref","first-page":"152104","DOI":"10.1016\/j.semarthrit.2022.152104","article-title":"The clinical features of juvenile dermatomyositis: a single-centre inception cohort","volume":"57","author":"Cancarini","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025110820503336400_keaf335-B21","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025110820503336400_keaf335-B22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/biom11030430","article-title":"Blood levels of galectin-9, an immuno-regulating molecule, reflect the severity for the acute and chronic infectious diseases","volume":"11","author":"Iwasaki-Hozumi","year":"2021","journal-title":"Biomolecules"},{"key":"2025110820503336400_keaf335-B23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","article-title":"CXCL10 and autoimmune diseases","volume":"8","author":"Lee","year":"2009","journal-title":"Autoimmun Rev"},{"key":"2025110820503336400_keaf335-B24","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/annrheumdis-2018-213497","article-title":"Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome","volume":"77","author":"van den Hoogen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025110820503336400_keaf335-B25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acr.22142","article-title":"Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"66","author":"Robinson","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2025110820503336400_keaf335-B26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/mus.24307","article-title":"Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy","volume":"51","author":"Van De Vlekkert","year":"2015","journal-title":"Muscle Nerve"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf335\/63519270\/keaf335.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5622\/63519270\/keaf335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5622\/63519270\/keaf335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:50:41Z","timestamp":1762653041000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/11\/5622\/8167900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf335","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,18]]}}}